Wednesday, February 8, 2012

Pfizer aggessively eyeing the Japanese Generic / API Market

Pfizer Japan has indicated that  it will shortly launch two active pharmaceutical ingredients (APIs)/three products in Japan. The three products to be launched are bicalutamide 80 mg tablets and anti-platelet agent sarpogrelate (Anplag) 50 mg and 100 mg tablets. Including these, Pfizer Japan’s has lined up a total of 18 API/35 products for launch in Japan.
Pfizer said that out of the APIs that had been approved, it is currently preparing for the launch of two other APIs, diabetes treatment glimepiride (Amaryl) and antiarrhythmic agent pilsicainide (Sunrythum).
The company plans to  increase its number of generic products in the future, and is aiming to expand the lineup to more than 100 to 200 agents by 2015.